Literature DB >> 6379356

A comparison of the antimuscarinic effects of pirenzepine and N-methylatropine on ganglionic and vascular muscarinic receptors in the rat.

J Wess, G Lambrecht, U Moser, E Mutschler.   

Abstract

The antimuscarinic properties of pirenzepine and N-methylatropine were evaluated in two intact preparations by measuring A) the inhibition of increase in mean arterial pressure evoked by McN-A-343 in pithed rats through activation of ganglionic muscarinic receptors and B) the inhibition of fall in arterial pressure evoked by methacholine in anaesthetized rats through activation of vascular muscarinic receptors. To characterize the antimuscarinic potencies of pirenzepine and N-methylatropine, for both antagonists doses were calculated that produce a 10-fold shift to the right of the dose-response curves for A) the pressor response to McN-A-343 (i.v. administration) in pithed rats (D10-p.r.) and B) for the depressor effect to methacholine (i.v. administration) in anaesthetized rats (D10-an.r.), respectively. Whereas N-methylatropine was virtually equieffective in blocking both muscarinic responses (D10-an.r./D10-p.r. approximately equal to 1), pirenzepine, however, was considerably more potent at ganglionic than at vascular muscarinic receptors (D10-an.r./D10-p.r. approximately equal to 16). These data confirm the existence of excitatory ganglionic muscarinic receptors with high affinity for pirenzepine (M1) and provide evidence for the presence of M2 receptors - receptors which show a low sensitivity to pirenzepine - on vascular smooth muscle cells. To further characterize the anticholinergic properties of pirenzepine, its effect on the pressor response to DMPP, a nicotinic ganglionic stimulant, was investigated in pithed rats. A high dose of pirenzepine (1.13 mumol/kg), given i.v., did not affect nicotinic ganglionic transmission.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379356     DOI: 10.1016/0024-3205(84)90249-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo.

Authors:  J Wess; P Angeli; C Melchiorre; U Moser; E Mutschler; G Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

2.  Mechanism Underlying Organophosphate Paraoxon-Induced Kinetic Tremor.

Authors:  Higor Alves Iha; Naofumi Kunisawa; Saki Shimizu; Misaki Onishi; Yuji Nomura; Nami Matsubara; Chihiro Iwai; Mizuki Ogawa; Mai Hashimura; Kazuaki Sato; Masaki Kato; Yukihiro Ohno
Journal:  Neurotox Res       Date:  2019-02-07       Impact factor: 3.911

3.  Structure-activity relationships of new analogues of arecaidine propargyl ester at muscarinic M1 and M2 receptor subtypes.

Authors:  U Moser; G Lambrecht; M Wagner; J Wess; E Mutschler
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

4.  Subclassification of muscarinic receptors in the heart, urinary bladder and sympathetic ganglia in the pithed rat. Selectivity of some classical agonists.

Authors:  K J van Charldorp; A de Jonge; M J Thoolen; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-12       Impact factor: 3.000

5.  Characterization of presynaptic vascular muscarinic receptors inhibiting endogenous noradrenaline overflow in the portal vein of the freely moving rat.

Authors:  R Remie; R P Coppes; H Meurs; A F Roffel; J Zaagsma
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

6.  Central and peripheral muscarinic actions of physostigmine and oxotremorine on avoidance responding of squirrel monkeys.

Authors:  J M Witkin
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Muscarinic activity of McN-A-343 and its value in muscarinic receptor classification.

Authors:  R M Eglen; B A Kenny; A D Michel; R L Whiting
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.